| Page 12 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

2023 AAMDSIF Patient and Family Conference in Dallas, TX

Join patients, families and caregivers for the 2023 Dallas, TX Patient and Family Conference This event is chaired and organized by Dr. Taha Bat from UT Southwestern.

Event Date: 
Sat, 11/04/2023 - 9:30am (EDT)
Conference Event Type: 

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Author(s): 
Zhang T, Auer P, Dong J, Cutler C, Dezern AE, Gadalla SM, Deeg HJ, Nazha A, Carlson KS, Spellman S, Bolon YT, Saber W
Primary Author: 
Zhang T
Journal Title: 
Journal of Hematology & Oncology
Original Publication Date: 
Apr 2023

Recurrent mutations in TP53, RAS pathway and JAK2 genes were shown to be highly prognostic of allogeneic hematopoietic cell transplant (alloHCT) outcomes in

Bone Marrow Disease(s): 

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Author(s): 
Zeidner JF, Mazerolle F, Norton J, Regnault A, Kristo F, Romero H, Fram RJ, Faller DV, Dalal M, Ades L, Sekeres MA.
Primary Author: 
Zeidner JF
Journal Title: 
Haematologica
Original Publication Date: 
Apr 2023
Bone Marrow Disease(s): 

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Author(s): 
Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T,
Primary Author: 
Garcia JS
Journal Title: 
Blood
Original Publication Date: 
Apr 2023

Two articles in this week’s issue focus on the use of ipilimumab and decitabine for patients with myelodysplasia (MDS) and

Bone Marrow Disease(s): 

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Author(s): 
Komrokji RS, Aguirre LE, Al-Ali N, Chan O, Xie Z, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Sallman DA
Primary Author: 
Komrokji RS
Journal Title: 
Blood Advances
Original Publication Date: 
Apr 2023
Bone Marrow Disease(s): 

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

Author(s): 
Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB
Primary Author: 
Al-Kali A
Journal Title: 
Blood Cancer
Original Publication Date: 
Apr 2023
Bone Marrow Disease(s): 

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Author(s): 
Mukherjee S, Dong W, Schiltz NK, Stange KC, Cullen J, Gerds AT, Carraway HE, Singh A, Advani AS, Sekeres MA, Koroukian SM
Primary Author: 
Mukherjee S
Journal Title: 
The Oncologist
Original Publication Date: 
Apr 2023

Background: Older patients with

Bone Marrow Disease(s): 

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

Author(s): 
Mukherjee S, Dong W, Schiltz NK, Stange KC, Cullen J, Gerds AT, Carraway HE, Singh A, Advani AS, Sekeres MA, Koroukian SM
Primary Author: 
Mukherjee S
Journal Title: 
The Oncologist
Original Publication Date: 
Apr 2023

Background: Older patients with

Bone Marrow Disease(s):